50 Years Of Global Health Progress – Interview With IFPMA Head Thomas Cueni 23/05/2018 by William New, Intellectual Property Watch Leave a Comment Dr Tedros Adhanom Ghebreyesus, WHO Director-General in his inaugural speech at the World Health Assembly this week, explained that partnerships are a key strategy for the WHO to ensuring healthy lives and promoting well-being for all at all ages. He added that the WHO is engaging with the private sector as a crucial partner in achieving health for all. Thomas Cueni, IFPMA’s Director General, in an interview with Health Policy Watch on the occasion of the IFPMA’s 50-year anniversary, explains how the research-based biopharmaceutical industry together with IFPMA have contributed to the huge strides in health progress over 50 years. He explains the major leaps forward, setbacks and mistakes, as well as how industry is part of the solution, as “do-ers” and partners in global health progress. Cueni also talks about pricing and cost of R&D.
World Health Assembly Begins Discussion On Access To Medicines 22/05/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment On the second day of this week’s annual World Health Assembly, delegates began discussing the issue of “shortages of, and access to, medicines and vaccines.” It is generally held that access to safe, efficacious, and affordable medicines is of paramount importance to achieve the United Nations Sustainable Development Goals by 2030, but there seems to be no expeditious solution, and no lack of divergent views on how to get there.
Global Antimicrobial Resistance R&D Hub Launched At Health Assembly 22/05/2018 by Damilola Adepeju for Intellectual Property Watch Leave a Comment Countries, organisations and foundations came together today alongside the annual World Health Assembly to launch the Global Antimicrobial Resistance and Development Hub (Global AMR R&D Hub).
Taiwan Left At Health Assembly Door; Police Ask Activists To Remove Political T-Shirts 22/05/2018 by Intellectual Property Watch 1 Comment For the second year in a row, Taiwan has not been invited to participate as an observer at the World Health Assembly taking place this week. Political dissent with China borne out of a change of government in Taiwan now refusing to recognise the “One China” principle resulted in Taiwan being left out of the World Health Organization. At the opening of the Assembly, several countries supported Taiwan, including the United States.
O Paradoxo Das Patentes No Brasil E Suas Implicações Para O Acesso A Medicamentos 22/05/2018 by Intellectual Property Watch 2 Comments O sistema de patentes foi supostamente projetado para permitir a recuperação do investimento em pesquisa e desenvolvimento (P&D) de um novo produto, através da venda sob exclusividade por um período de tempo. Vários estudos relacionaram preços altos de medicamentos à situação de monopólio estabelecida pelo sistema de patentes e outros direitos de monopólio (como a exclusividade de dados). É bastante estabelecido que a existência de uma patente pode levar a preços altos devido à condição de mercado em que um produtor pode operar com exclusividade. Vários estudos relacionaram preços elevados de medicamentos à situação de monopólio estabelecida pelo sistema de patentes e outros direitos de monopólio (como a exclusividade de dados). Na ausência de concorrência, um produtor pode cobrar praticamente qualquer preço pelo seu produto. A concorrência, portanto, pode promover uma redução significativa de preços e aumentar o acesso.
US Patent System Remains 1st In The World, Despite Errors In Chamber Rankings 21/05/2018 by Intellectual Property Watch 1 Comment Over the past few months, US officials ranging from PTO Director Andrei Iancu to a number of Congressional members, most recently Rep. Kelly (Illinois-2), have cited to the Chamber of Commerce’s ranking of intellectual property systems, which has dropped the US patent system from 1st in the world to 12th. They cite the rankings as evidence that the US patent system is in urgent need of review. Unfortunately, the rankings are based on misinterpretations and falsehoods. These are worth noting ahead of a House Judiciary hearing Tuesday with Iancu testifying.
WHO Director Dr Tedros Opens First Annual World Health Assembly With ‘Keys For Success’ 21/05/2018 by Catherine Saez, Intellectual Property Watch 1 Comment World Health Organization Director General Tedros Adhanom Ghebreyesus (“Dr Tedros”) in his first speech in his function at head of the World Health Assembly described three keys to reach the ambitious goals of the organisation. He envisioned a transformed WHO helped by a strong leadership team, called for political commitment for which he said most country leaders are ready, and advocated partnerships with a number of international health actors, including the private sector.
Global Influenza Initiative Celebrates 10 Years, Adds Former WHO Official 21/05/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment As the annual World Health Assembly opened today, a global initiative for sharing influenza genetic data celebrated its tenth anniversary and announced new senior advisors for international affairs and biosecurity issues, one of which is Marie-Paule Kieny, former World Health Organization Assistant Director-General for Health Systems and Innovation.
AI Takes Multidimensional Role In Emergency Response And Outbreaks 20/05/2018 by Damilola Adepeju for Intellectual Property Watch 1 Comment In an age where emphasis on the use of artificial intelligence (AI) for the good of humanity is increasing, last week’s AI for Good Global Summit at the International Telecommunication Union (ITU) brought leading experts together to demonstrate the multidimensionality of AI in emergency response and outbreaks, as well as in risk reduction.
Five Years After The Indian Supreme Court’s Novartis Verdict 20/05/2018 by Patralekha Chatterjee for Intellectual Property Watch 13 Comments On 1 April 2013, in a packed room inside India’s Supreme Court, a magnificent building in Indo-British architectural style, two judges delivered a verdict that impacted the national and global conversation about patents and patients. India’s apex court delivered a 112-page landmark judgement which dismissed Swiss pharma giant Novartis AG’s appeal for a patent for its life-saving cancer drug marketed under brand name Glivec in most parts of the world. The Novartis case triggered a hugely polarising discourse around the world about a key feature of India’s patent regime.